PRGO has been the topic of several other research reports. Royal Bank of Canada raised Perrigo from an underperform rating to a sector perform rating and lifted their price target for the stock from $64.00 to $86.00 in a research report on Friday, November 10th. Jefferies Group set a $71.00 price target on Perrigo and gave the stock a hold rating in a research report on Sunday, October 29th. Canaccord Genuity set a $100.00 price target on Perrigo and gave the stock a buy rating in a research report on Monday, January 1st. Barclays lifted their price target on Perrigo to $93.00 and gave the stock an overweight rating in a research report on Monday, December 4th. Finally, BidaskClub lowered Perrigo from a hold rating to a sell rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $93.47.
Perrigo (NYSE PRGO) opened at $89.55 on Friday. The company has a market capitalization of $12,612.31, a P/E ratio of -9.78, a price-to-earnings-growth ratio of 1.91 and a beta of 0.76. Perrigo has a 12-month low of $63.68 and a 12-month high of $95.93. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.24 and a current ratio of 1.72.
In related news, EVP John Wesolowski sold 450 shares of Perrigo stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $83.09, for a total value of $37,390.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Todd W. Kingma sold 1,500 shares of Perrigo stock in a transaction that occurred on Thursday, December 28th. The shares were sold at an average price of $88.52, for a total value of $132,780.00. Following the completion of the sale, the vice president now owns 19,565 shares in the company, valued at $1,731,893.80. The disclosure for this sale can be found here. Insiders sold a total of 3,838 shares of company stock worth $336,784 over the last quarter. Company insiders own 6.90% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Greenlight Capital Inc. boosted its stake in shares of Perrigo by 14.8% in the third quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock valued at $245,572,000 after buying an additional 374,032 shares in the last quarter. Parnassus Investments CA boosted its stake in shares of Perrigo by 7.1% in the third quarter. Parnassus Investments CA now owns 2,257,000 shares of the company’s stock valued at $191,055,000 after buying an additional 150,000 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Perrigo by 90.5% in the fourth quarter. Victory Capital Management Inc. now owns 2,046,980 shares of the company’s stock valued at $178,414,000 after buying an additional 972,210 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Perrigo by 23.5% in the fourth quarter. Millennium Management LLC now owns 1,478,782 shares of the company’s stock valued at $128,891,000 after buying an additional 281,267 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Perrigo by 356.7% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,436,621 shares of the company’s stock valued at $125,216,000 after buying an additional 1,122,068 shares in the last quarter. Hedge funds and other institutional investors own 83.27% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Perrigo (PRGO) a $107.00 Price Target” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/19/cantor-fitzgerald-analysts-give-perrigo-prgo-a-107-00-price-target.html.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.